Health Condition 1: N040- Nephrotic syndrome with minor glomerular abnormality
Conditions
Interventions
Intervention1: Addition of short course of oral enalapril: Participants in this group will receive oral enalapril at a dose of 0.3 mg/kg/day for a duration of 3 days along with standard treatment.The
Sponsors
Surya Prasath.R
Eligibility
Inclusion criteria
Inclusion criteria: Patients aged between 1 to 18 years present to pediatric OPD/IPD with infrequently relapsing nephrotic syndrome. Proteinuria =3+ in dipstick urine test for 3 days Patients who have not received antiproteinuric medications (Amiloride and Enalapril) for the past 4 weeks. Willingness of the patient or guardian to provide informed consent.
Exclusion criteria
Exclusion criteria: Patients with a history of ACEI allergy or intolerance. Patients with renal artery stenosis Patients with a GFR less than 30ml/min Patients with liver failure or hepatic impairment. Patients with a history of malignant hypertension.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome measure for this study will be the duration of proteinuria till remission. This will be measured as the number of days from the start of treatment to the first day of three consecutive negative or trace urine dipstick tests for proteinTimepoint: Till remission | — |
Secondary
| Measure | Time frame |
|---|---|
| The change in proteinuria from baseline to week 3, 6 and 12 The change in serum albumin from baseline to week 3, 6 and 12 The change in blood pressure from baseline to week 3, 6 and 12 The incidence of adverse events related to enalapril if any Total cumulative steroid doses required in both groups to achieve remission Total number of relapses during the studyTimepoint: Week 3,6,12 | — |
Countries
India
Contacts
Public ContactDrPrateek Kumar Panda
AIIMS Rishikesh
Outcome results
None listed